ImmunoGen’s Elahere Doubles Response Rate Versus Chemo in Phase III Ovarian Cancer Trial
June 4, 2023 9:30 pmCHICAGO – Twice as many patients with folate receptor alpha (FRα)-positive, advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer responded to ImmunoGen’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) than did patients on chemotherapy in a confirmatory Phase III trial.… Read more